A psychedelic used in some countries to treat post-traumatic stress disorder is expected to get a closer examination from the federal government on its safety and effectiveness, CBS News’ Jennifer Jacobs and Celine Gounder report, citing sources. The White House is drafting an executive order that would signal the Trump administration’s willingness to further U.S. research into a drug called ibogaine, the authors add. Ibogaine, a naturally occurring compound from a shrub native to Africa, is used to treat depression, anxiety, addiction, post-traumatic stress disorder and brain trauma. Clearmind Medicine (CMND), AtaiBeckley (ATAI), Cybin (HELP), Definium Therapeutics (DFTX), GH Research (GHRS), Compass Pathways (CMPS) and Psyence Biomedical (PBM) are trading higher following the news.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMND:
- Psychedelic: Clearmind’s CMND-100 meets primary endpoint in trial
- Clearmind announces DSMB recommendation to continue CMND-100 trial
- Morning Movers: Globalstar climbs following deal to be acquired by Amazon
- Clearmind Medicine announces CMND-100 meets primary endpoint
- Psychedelic: Clearmind completes treatment, follow-up for CMND-100 trial